文献速递泌尿生殖与妇科肿瘤放疗

多中心评估自动化输送系统术中计划前列腺近距离放疗的生化无复发生存结局

Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-06-06

该多中心研究分析了2003至2013年间3个中心2608例接受术中计划低剂量率前列腺近距离放疗(IO-LDRB)作为单一疗法的低危或低级别中危前列腺癌患者,中位随访4.7年,7年预测生化无复发生存率为93%,生化复发仅依赖D90和前列腺特异性抗原密度。

要点

  • IO-LDRB治疗后7年预测bRFS达93%,生化复发率低(4.8%)。
  • Cox回归显示bRFS仅与植入时D90和PSA密度相关。
  • 结果与已发表的手工预计划技术结果相比具有优势。

核心结论

  • IO-LDRB是低危和低级别中危前列腺癌的有效治疗选择,治疗后多年生化复发率保持低位。

研究设计与样本

  • 多中心前瞻性数据库分析,纳入2003至2013年间3个中心2608例接受IO-LDRB单一治疗的低危或低级别中危前列腺癌患者。

主要发现

  • 中位随访4.7年(四分位距3.1-6.9年),124例(4.8%)出现生化复发,中位失败时间4.0年。
  • 7年预测生化无复发生存率为93%。
  • Cox回归显示bRFS仅依赖植入时D90和前列腺特异性抗原密度。

关键数值与推荐

  • 中位年龄64岁(范围42-84),中位初始PSA 5.5 ng/mL,74%为T1、26%为T2,73%为Gleason 6、25%为Gleason 7。
  • 中位种子活度0.437 mCi,D90为186.7 Gy,V100为99.37%。

临床怎么用

  • 对于低危和低级别中危前列腺癌,IO-LDRB可作为单一治疗选择,术中应关注D90和PSA密度以预测生化复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report biochemical recurrence in prostate cancer treated with intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB). METHODS AND MATERIALS: Between 2003 and 2013, 2608 patients from 3 centers were treated with IO-LDRB as single-modality treatment for low or low-tier intermediate-risk prostate cancer. Databases from the 3 centers have been analyzed. These independent databases were collected prospectively. Patient, tumor, and treatment characteristics were then compared, Kaplan-Meier survival estimates of biochemical relapse-free survival (bRFS) were generated, and the Cox proportional hazards model was used to determine factors predicting for relapse. RESULTS: A total of 2608 patients with a median follow-up of 4.7 (interquartile range, 3.1-6.9) years were analyzed. Median age was 64 (range, 42-84) years. In these patients, median initial prostate-specific antigen was 5.5 ng/mL, 74% were T1, and 26% were T2; 73% were Gleason 6, and 25% Gleason 7. Median percentage of biopsy cores positive was 33%, and median gland volume was 34.2 cm3. Eleven percent of patients received hormones for a median of 3.0 months before implantation. Median seed activity was 0.437 mCi, D90 (dose covering 90% of the prostate volume) was 186.7 Gy, and V100 was 99.37%. Biochemical relapse was observed in 124 patients (4.8%), and median time to failure was 4.0 years. Predicted bRFS was 93% at 7 years. On Cox regression bRFS was dependent only on D90 at the time of implantation and prostate-specific antigen density. CONCLUSIONS: This study demonstrates that IO-LDRB is an effective treatment option for patients with low and low-tier intermediate-risk prostate cancer. Rates of biochemical relapse remain low several years after treatment. These results compared favorably to published manual preplan technique results.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Martell K, Husain S, Taussky D, et al. Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System. Int J Radiat Oncol Biol Phys. 2017. PMID: 28807532. doi:10.1016/j.ijrobp.2017.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。